

## Labetalol

<b>CAUTION: High Administration Risk Rating</b>	
<b>Form</b>	100mg per 20mL ampoule
<b>Reconstitution</b>	Already in solution
<b>Compatibility &amp; Stability</b>	Glucose 5% Sodium Chloride 0.9%
<b>Administration</b>	<p>The solution should be clear and colourless. Inspect visually for particulate matter or discoloration prior to administration and discard if present.</p> <p><b><u>IV Injection</u></b> Emergency use only. Use undiluted at a maximum rate of 50mg/min. Usual maximum total dose 200mg.</p> <p><b><u>IV infusion</u></b> Withdraw and discard 10 mL from a 250 mL infusion bag containing compatible infusion fluid. Withdraw 300 mg (60 mL) of labetalol injection solution from three ampoules using a syringe and add to the remaining 240 mL of infusion fluid and mix well. This gives a solution containing approximately 1 mg/mL</p> <p>Infuse the prescribed dosage using a rate-controlled infusion pump. Refer to CCU/Pharmacy for guidance.</p>
<b>Monitoring</b>	Monitor blood pressure, heart rate, ECG, respiratory function.
<b>Extravasation</b>	Extravasation may cause tissue damage. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely. Re-site cannula at first signs of inflammation.
<b>Additional Information</b>	<div style="border: 1px solid blue; padding: 5px; text-align: center; margin-bottom: 10px;"> <b>For obstetric patients refer to CUMH guidelines or the Pharmacy Department</b> </div> <p>Patient should avoid upright position during and for 3 hours after intravenous administration.</p>

**Information provided relates to Trandate® manufactured by RPH Pharmaceuticals.**